While You Were Paying $26,500 a Year for Injections, Scientists Found the Brain's Own 'Self-Cleaning Switch'

Scientists at Sweden's Karolinska Institute and Japan's RIKEN Center for Brain Science discovered that somatostatin receptors SST1 and SST4 regulate neprilysin enzyme levels, which degrade amyloid beta — the main culprit behind Alzheimer's. These two receptors work redundantly in the hippocampus, and stimulation in mouse models showed amyloid reduction and memory improvement. The key insight is that healthy brains maintain this system naturally, but it collapses in Alzheimer's patients as somatostatin levels drop.

SST1 and SST4 belong to the G protein-coupled receptor (GPCR) family, and roughly 34% of all marketed drugs target GPCRs. Blood pressure medications, acid reflux drugs, and asthma treatments are all GPCR-based — oral, mass-producible, and affordable. This means developing an oral pill for Alzheimer's is technically feasible, potentially replacing $26,500/year IV antibody treatments and opening access to patients in low- and middle-income countries where over 60% of the world's dementia patients reside.

Lecanemab ($26,500/year) and donanemab ($32,000/year) are FDA-approved but carry real burdens. Including mandatory brain MRIs and PET scans, actual patient costs can reach $82,500/year. Lecanemab only slows cognitive decline by 27%, while 30.5% of donanemab trial participants showed brain abnormalities. In 2024, more than half of U.S. neurologists declined to recommend lecanemab, reflecting the structural problems of Big Pharma's monopolistic high-price strategy.

Current antibody treatments can only be administered after symptoms appear and show limited effects in early stages only. If a GPCR-based pill is developed, preventive administration to high-risk populations (e.g., APOE4 gene carriers) starting in middle age becomes possible. Like taking statins for cholesterol, an era of managing amyloid through daily oral medication could emerge, representing a paradigm shift from treatment to prevention.

A January 2026 follow-up study revealed that the LilrB2 receptor acts as a common target for both amyloid beta and inflammatory proteins, signaling neurons to eliminate essential synapses. This suggests Alzheimer's isn't just about amyloid accumulation — it's a disease where amyloid hijacks the brain's synaptic pruning system. This supports the argument that blocking amyloid production upstream via SST1/SST4 may be fundamentally superior to attacking accumulated amyloid with antibodies.